Matsuno K, Senda T, Matsunaga K, Mita S
New Drug Research, Central Research Laboratories, Santen Pharmaceutical Co., Ltd., Osaka, Japan.
Eur J Pharmacol. 1994 Aug 11;261(1-2):43-51. doi: 10.1016/0014-2999(94)90298-4.
Three sigma receptor ligands were examined for their ameliorating effects on p-chloroamphetamine-induced amnesia in mice. p-Chloroamphetamine was administered intraperitoneally 30 min before the training session of the passive avoidance response. Each sigma receptor ligand was administered 60 min before or immediately after the training session, or 60 min before the retention test. (+)-N-Allylnormetazocine ((+)-SKF-10,047), a prototype benzomorphan sigma receptor ligand, significantly reduced the p-chloroamphetamine-induced amnesia in these three administration schedules, as do acetylcholinesterase inhibitors. On the contrary, the significant anti-amnesic effects elicited by non-benzomorphan sigma receptor ligands, 1,3-di-(2-tolyl)guanidine (DTG) or (+)-3-(3-hydroxyphenyl)-N-(1-propyl)piperizine ((+)-3-PPP), were observed depending upon the timing of their administration. In addition, the ameliorating effect of (+)-SKF-10,047 against the p-chloroamphetamine-induced amnesia was superior to that of (-)-SKF-10,047. The (+)-SKF-10,047-induced anti-amnesic effect was significantly antagonized by the concurrent administration of either scopolamine, a muscarinic receptor antagonist, or hemicholinium-3, an inhibitor of the Na(+)-dependent high-affinity choline uptake site. These findings indicated that sigma receptor ligands had anti-amnesic effects against drug-induced memory impairment. In addition, the anti-amnesic effect of (+)-SKF-10,047 was superior to those of other sigma receptor ligands, and was mediated by both the sigma receptor and the central acetylcholinergic system.
研究了三种σ受体配体对小鼠对氯苯丙胺诱导的失忆症的改善作用。在被动回避反应训练前30分钟腹腔注射对氯苯丙胺。每种σ受体配体在训练前60分钟或训练后立即给药,或在记忆测试前60分钟给药。原型苯并吗啡烷σ受体配体(+)-N-烯丙基去甲左啡诺((+)-SKF-10,047)在这三种给药方案中均能显著减轻对氯苯丙胺诱导的失忆症,乙酰胆碱酯酶抑制剂也有同样效果。相反,非苯并吗啡烷σ受体配体1,3-二(2-甲苯基)胍(DTG)或(+)-3-(3-羟基苯基)-N-(1-丙基)哌嗪((+)-3-PPP)的显著抗失忆作用则取决于给药时间。此外,(+)-SKF-10,047对氯苯丙胺诱导的失忆症的改善作用优于(-)-SKF-10,047。同时给予毒蕈碱受体拮抗剂东莨菪碱或Na(+)-依赖性高亲和力胆碱摄取位点抑制剂半胱氨酸-3,可显著拮抗(+)-SKF-10,047诱导的抗失忆作用。这些发现表明,σ受体配体对药物诱导的记忆损伤具有抗失忆作用。此外,(+)-SKF-10,047的抗失忆作用优于其他σ受体配体,且由σ受体和中枢乙酰胆碱能系统介导。